Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol

被引：31
|
作者：
Barnes, Theresa [1 ]
Moots, Robert [1 ]
机构：
[1] Univ Liverpool, Acad Rheumatol, Liverpool L69 3BX, Merseyside, England
来源：
INTERNATIONAL JOURNAL OF NANOMEDICINE | 2007年 / 2卷 / 01期
基金：
英国医学研究理事会;
关键词：
certolizumab pegol; TNF alpha; rheumatoid arthritis; nanomolecule;
D O I：
10.2147/nano.2007.2.1.3
中图分类号：
TB3 [工程材料学];
学科分类号：
0805 ; 080502 ;
摘要：
Anti-TNF alpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNF alpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNF alpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
引用
收藏
页码：3 / 7
页数：5
相关论文
共 50 条
  • [31] Systemic Sarcoidosis Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis: A Case Report and Review of the Literature
    Koda, Keigo
    Toyoshima, Mikio
    Nozue, Tsuyoshi
    Suda, Takafumi
    INTERNAL MEDICINE, 2020, 59 (16) : 2015 - 2021
  • [32] Cimzia (certolizumab pegol), Simponi (golimumab) The next generation of monoclonal antibody treatment for rheumatoid arthritis
    Nolan, Mark
    EJHP PRACTICE, 2010, 16 (06): : 52 - 53
  • [33] THE EFFICACY OF CERTOLIZUMAB PEGOL ADDED TO METHOTREXATE IS SUSTAINED OVER 2 YEARS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
    Keystone, Edward C.
    Fleischmann, Roy
    Smolen, Josef
    Strand, V.
    Landewe, Robert
    Combe, Bernard
    Mease, Philip
    Ansari, Zainab
    Goel, Niti
    van der Heijde, Desiree
    Emery, Paul
    RHEUMATOLOGY, 2010, 49 : I105 - I105
  • [34] HOW GOOD ELDERLY RHEUMATOID ARTHRITIS PATIENTS RESPOND AT FIRST YEAR OF TREATMENT WITH CERTOLIZUMAB PEGOL?
    Torrente-Segarra, V.
    Prada, M. Fernandez
    Exposito, R.
    Punal, N. Garrido
    Sanchez-Andrade, A.
    Lamua-Riazuelo, J. R.
    Olive, A.
    Tovar, J. V.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 964 - 965
  • [35] The Efficacy of Certolizumab Pegol Added to Methotrexate is Sustained Over 2 Years in the Treatment of Rheumatoid Arthritis
    Keystone, Edward
    Fleischmann, Roy
    Smolen, Joseph
    Strand, Vibeke
    Landewe, Robert
    Combe, Bernard
    Mease, Philip
    Ansari, Zainab
    Goel, Niti
    Van der Heijde, Desiree
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (06) : 1332 - 1333
  • [36] Certolizumab Pegol and Psoriatic Arthritis
    不详
    JOURNAL OF DRUGS IN DERMATOLOGY, 2013, 12 (01) : 128 - 129
  • [37] Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis
    Morita, Takayoshi
    Fujimoto, Kosuke
    Shima, Yoshihito
    Ogata, Atsushi
    Kumanogoh, Atsushi
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (09)
  • [38] EVALUATION OF COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL COMPARED WITH ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN COLOMBIA
    Guzman, R.
    Jaramillo, L. F.
    Otero, W.
    VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [39] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, AND PSORIATIC ARTHRITIS IN ROMANIA
    Codreanu, C.
    Mogosanu, C.
    Joita, M.
    Purcaru, O.
    VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
  • [40] Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report
    Horai, Yoshiro
    Ishikawa, Hiroshi
    Iwanaga, Nozomi
    Izumi, Yasumori
    Matsuoka, Yuki
    Miura, Shiro
    Kawakami, Atsushi
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 (05) : 1179 - 1182
12345